Cabometyx 60 MG tablet 30S
Ended Awarded
- Contract number
- SPE2DR26FJUS8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,772
Award facts
- Contract value 100% obligated
- $16,772.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $16.8K to DMS Pharmaceutical Group Inc. for 30 tablets of Cabometyx 60 mg on November 18, 2025, with completion due by November 19, 2025. Cabometyx is a branded oncology medication used in cancer treatment, reflecting the Department of Defense's need for specialized pharmaceutical products to support military healthcare operations. This award utilized firm fixed-price pricing with no set-aside designation, indicating the contract was competed among all eligible vendors. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected as the prime contractor with no subcontractors identified.
This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion federal acquisition strategy designed to supply pharmaceutical products to military healthcare facilities worldwide. DMS Pharmaceutical Group's IDC, awarded November 13, 2025, carries a $500M ceiling value and extends through December 31, 2036, comprising a 30-month base period with three 30-month option periods. The company's established performance on numerous delivery orders across diverse pharmaceutical categories—including biologics, vaccines, specialty medications, and medical consumables—demonstrates its capability to fulfill the specialized requirements of the Department of Defense's military medical system.
Quick answers
Who was awarded contract SPE2DR26FJUS8?
SPE2DR26FJUS8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 18, 2025.
How much is contract SPE2DR26FJUS8 worth?
The government has obligated $16,772 on SPE2DR26FJUS8.
Is contract SPE2DR26FJUS8 an order under another contract?
Yes. SPE2DR26FJUS8 is a delivery order under SPE2DR25D9329, an indefinite delivery contract.
Was contract SPE2DR26FJUS8 competed?
The extent of competition for SPE2DR26FJUS8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award